Montelunio (Montelukast)

Montelukast, the active ingredient in Montelunio, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients who require anti‑inflammatory and bronchodilatory therapy. GNH USA supplies Montelunio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control respiratory and allergic conditions. - Asthma: improves control of chronic asthma and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain: occasional discomfort. - Diarrhoea: mild gastrointestinal upset. - Cough: non‑productive. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Allergic reactions: including angioedema or anaphylaxis. - Neuropsychiatric events: such as agitation, depression or suicidal thoughts. - Hepatotoxicity: elevated liver enzymes in rare cases. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions. - Hypersensitivity: avoid if the patient has known allergy to montelukast or any formulation component. - Neuropsychiatric monitoring: observe for mood changes, depression or suicidal ideation. - Hepatic function: assess liver enzymes in patients with pre‑existing liver disease. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Montelukast may interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Phenobarbital or rifampicin: may reduce montelukast plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole): potential increase in exposure.

Moderate Interactions (Monitor Closely): - Warfarin: occasional alteration of INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilatory effect; assess clinical response. - Other leukotriene modifiers: combined use may increase risk of adverse effects.